Patents by Inventor Horst G. Zerbe
Horst G. Zerbe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220395452Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.Type: ApplicationFiled: April 28, 2022Publication date: December 15, 2022Applicant: INTELGENX CORP.Inventors: Nadine PAIEMENT, Horst G. ZERBE, Justin W. CONWAY, Rodolphe OBEID, Ludwig AIGNER, Johanna MICHAEL
-
Publication number: 20220362164Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.Type: ApplicationFiled: April 26, 2022Publication date: November 17, 2022Applicant: INTELGENX CORP.Inventors: Nadine PAIEMENT, Horst G. ZERBE, Justin W. CONWAY, Rodolphe OBEID
-
Patent number: 10722476Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.Type: GrantFiled: March 5, 2018Date of Patent: July 28, 2020Assignee: Intelgenx Corp.Inventors: Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
-
Publication number: 20200215063Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.Type: ApplicationFiled: March 17, 2020Publication date: July 9, 2020Applicant: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement, Angela Angusti, Cormac Long, Rodolphe Obeid, Laetitia Rodes, Billal Tir
-
Patent number: 10610528Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.Type: GrantFiled: February 7, 2017Date of Patent: April 7, 2020Assignee: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement, Angela Angusti, Cormac Long, Rodolphe Obeid, Laetitia Rodes, Billal Tir
-
Publication number: 20190290595Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.Type: ApplicationFiled: June 14, 2019Publication date: September 26, 2019Applicant: Intelgenx Corp.Inventors: Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
-
Publication number: 20190133925Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.Type: ApplicationFiled: September 14, 2018Publication date: May 9, 2019Applicant: Intelgenx Corp.Inventors: Nadine Paiement, Horst G. Zerbe, Justin W. Conway, Rodolphe Obeid, Ludwig Aigner, Johanna Michael
-
Publication number: 20180250240Abstract: Disclosed is a method of administration and device for the improved bioavailability of leukotriene receptor antagonists. This method and device involve an alkaline surface pH oral film dosage form designed to deliver leukotriene receptor antagonists, such as Montelukast, to the stomach in an amorphous precipitate suspended in aqueous medium. Also disclosed is a device and method for treating a disease, such as a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having an alkaline surface pH film layer and a safe and effective amount of Montelukast. The device is configured and formulated to predominantly achieve enteral delivery of the Montelukast. The method includes enterally delivering to a human or an animal in need of treatment, a safe and effective amount of Montelukast capable of crossing the blood-brain barrier.Type: ApplicationFiled: March 29, 2018Publication date: September 6, 2018Applicant: Intelgenx Corp.Inventors: Nadine Paiement, Horst G. Zerbe, Justin W. Conway, Rodolphe Obeid
-
Publication number: 20180228738Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.Type: ApplicationFiled: March 5, 2018Publication date: August 16, 2018Applicant: Intelgenx Corp.Inventors: Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
-
Publication number: 20180110738Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.Type: ApplicationFiled: October 20, 2016Publication date: April 26, 2018Applicant: lntelgenx Corp.Inventors: Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
-
Publication number: 20180110724Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.Type: ApplicationFiled: December 20, 2017Publication date: April 26, 2018Applicant: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement, Cormac Long, Rodolphe Obeid
-
Patent number: 9949934Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.Type: GrantFiled: October 20, 2016Date of Patent: April 24, 2018Assignee: Intelgenx Corp.Inventors: Horst G. Zerbe, Rodolphe Obeid, Justin W. Conway, Nadine Paiement, Ludwig Aigner
-
Publication number: 20180078549Abstract: Improved pharmaceutical solid oral dosage forms for the buccal and/or sublingual delivery of Tadalafil. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced methods of preparation by the use improved solubilization systems which can maintain the Tadalafil in a buccal and/or sublingual oral dosage form or a polymeric film matrix that provides improved bioavailability and/or absorption of Tadalafil.Type: ApplicationFiled: November 27, 2017Publication date: March 22, 2018Applicant: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement, Angela Angusti, Cormac Long
-
Publication number: 20170157119Abstract: Oral film dosage forms that provide improved solubilization and stabilization of an active ingredient in particle form include at least one primary crystallization inhibitor in an amount that inhibits growth and/or agglomeration of the active ingredient, a polyoxyethylated fatty acid glycerides in an amount that further enhances inhibition of crystallization, growth and agglomeration of the particles of the pharmaceutically active ingredient; and at least one plasticizer present in an amount that is effective to increase flexibility and elasticity of the film dosage form.Type: ApplicationFiled: February 7, 2017Publication date: June 8, 2017Applicant: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement, Angela Angusti, Cormac Long, Rodolphe Obeid
-
Patent number: 9301948Abstract: An instantly wettable and rapidly disintegrating oral film dosage form without a surfactant and without a polyalcohol was achieved by combining at least one water soluble polymer that is not a copolymer of vinylpyrrolidone, at least one active agent, a copolymer of vinylpyrrolidone and titanium dioxide. In certain embodiments, the film comprises hydroxypropyl cellulose or a combination of hydroxypropyl cellulose and a polymer or copolymer of vinylpyrrolidone or a substituted vinylpyrrolidone as the water soluble polymer(s). A plasticizer, and optional additives selected from synthetic sweeteners, natural sweeteners, flavorants, antioxidants, colorants, and opacifiers, can be added to the disclosed film oral dosage forms.Type: GrantFiled: July 30, 2014Date of Patent: April 5, 2016Assignee: IntelGenx Corp.Inventors: Horst G. Zerbe, Angela Angusti, Nadine Paiement
-
Publication number: 20150038540Abstract: An instantly wettable and rapidly disintegrating oral film dosage form without a surfactant and without a polyalcohol was achieved by combining at least one water soluble polymer that is not a copolymer of vinylpyrrolidone, at least one active agent, a copolymer of vinylpyrrolidone and titanium dioxide. In certain embodiments, the film comprises hydroxypropyl cellulose or a combination of hydroxypropyl cellulose and a polymer or copolymer of vinylpyrrolidone or a substituted vinylpyrrolidone as the water soluble polymer(s). A plasticizer, and optional additives selected from synthetic sweeteners, natural sweeteners, flavorants, antioxidants, colorants, and opacifiers, can be added to the disclosed film oral dosage forms.Type: ApplicationFiled: July 30, 2014Publication date: February 5, 2015Applicant: IntelGenx Corp.Inventors: Horst G. Zerbe, Angela Angusti, Nadine Paiement
-
Patent number: 8735374Abstract: A direct compression formulation suitable for preparing buccal and/or sublingual and dosage forms incorporates a combination of a non-ionic polymeric solubility enhancer, a mucoadhesive polymer, a filler, a disintegrant, and a pharmaceutically active agent. Cannabinoid-cyclodextrin complexes exhibiting an improved property selected from improved stability, higher product yield and improved product uniformity may be obtained by complexing the cannabinoid with the cyclodextrin in a liquid medium containing an antioxidant. To enhance stability, product yield and/or product uniformity, complexing may be done while the liquid medium is in contact with an atmosphere having a very low oxygen content.Type: GrantFiled: July 15, 2010Date of Patent: May 27, 2014Assignee: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement
-
Patent number: 8703191Abstract: Controlled-release tablets exhibiting excellent storage stability are achieved by granulating a pharmaceutically active agent with a hydroxyalkylcelluose, blending the resulting granules with an extragranular phase composed of a particulate material that provides a sustained-release matrix, and compressing the blend into a tablet form, which may be optionally coated, such as with an enteric coating composition, to provide delayed release and/or to enhance stability of the active agent.Type: GrantFiled: July 25, 2007Date of Patent: April 22, 2014Assignee: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement
-
Patent number: 8691272Abstract: A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive tablet compression techniques.Type: GrantFiled: December 28, 2006Date of Patent: April 8, 2014Assignee: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement, Pompilia Lspas-Szabo
-
Publication number: 20140065217Abstract: A multilayer oral dosage form that provides controlled release of an active compound includes a non-erodible core containing a pharmaceutically active compound and/or a nutritionally active compound, and at least one release-modulating layer laminated to each side of the core layer. The dosage form can be prepared using simple, inexpensive tablet compression techniques.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: Intelgenx Corp.Inventors: Horst G. Zerbe, Nadine Paiement, Pompilia Ispas-Szabo